Pharmacy Cagrilintide monotherapy led to ~11.8% weight loss vs 2.3% with placebo over 68 weeks in the phase 3 REDEFINE 1 trial for adults with obesity or overweight plus comorbidities. Read more CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme What is the pipeline for future medications for obesity? International Journal of Obesity